iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.710
+0.070 (4.27%)
At close: May 8, 2026, 4:00 PM EDT
1.730
+0.020 (1.17%)
After-hours: May 8, 2026, 7:59 PM EDT
iBio, Inc. Revenue
iBio, Inc. had revenue of $300.00K in the twelve months ending December 31, 2025, down -20.00% year-over-year. In the fiscal year ending June 30, 2025, iBio, Inc. had annual revenue of $400.00K with 77.78% growth.
Revenue (ttm)
$300.00K
Revenue Growth
-20.00%
P/S Ratio
206.02
Revenue / Employee
$15,000
Employees
20
Market Cap
61.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 400.00K | 175.00K | 77.78% |
| Jun 30, 2024 | 225.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | 1.64M | -380.00K | -18.83% |
| Jun 30, 2019 | 2.02M | 1.57M | 354.50% |
| Jun 30, 2018 | 444.00K | 50.00K | 12.69% |
| Jun 30, 2017 | 394.00K | -554.00K | -58.44% |
| Jun 30, 2016 | 948.00K | -903.00K | -48.78% |
| Jun 30, 2015 | 1.85M | 1.65M | 802.93% |
| Jun 30, 2014 | 205.00K | -802.00K | -79.64% |
| Jun 30, 2013 | 1.01M | -270.00K | -21.14% |
| Jun 30, 2012 | 1.28M | 756.92K | 145.54% |
| Jun 30, 2011 | 520.08K | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | 1.18M | 189.54K | 19.20% |
| Jun 30, 2008 | 987.06K | 90.79K | 10.13% |
| Jun 30, 2007 | 896.27K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MindWalk Holdings | 20.70M |
| Immutep | 5.28M |
| BeyondSpring | 1.88M |
| ImageneBio | 800.00K |
| MediciNova | 409.66K |
| Entera Bio | 42.00K |
| Impact BioMedical | 32.00K |
IBIO News
- 4 weeks ago - iBio, Inc. Transcript: Status update - Transcripts
- 4 weeks ago - iBio receives regulatory clearance to initiate IBIO-600 trial in Australia - TheFly
- 4 weeks ago - iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia - GlobeNewsWire
- 5 weeks ago - Biotech Alert: Searches spiking for these stocks today - TheFly
- 7 weeks ago - iBio, Inc. Transcript: Study update - Transcripts
- 7 weeks ago - iBio to provide update on cardiopulmonary program - TheFly
- 7 weeks ago - iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - GlobeNewsWire
- 2 months ago - iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026 - Transcripts